4.7 Article

COVID-19 in patients with lung cancer

Journal

ANNALS OF ONCOLOGY
Volume 31, Issue 10, Pages 1386-1396

Publisher

ELSEVIER
DOI: 10.1016/j.annonc.2020.06.007

Keywords

chemotherapy; COVID-19; immunotherapy/checkpoint blockade; lung cancer; small molecule agents

Categories

Funding

  1. Memorial Sloan Kettering Cancer Center Support Grant/Core [P30CA008748]
  2. Druckenmiller Center for Lung Cancer Research at Memorial Sloan Kettering Cancer Center
  3. National Institutes of Health [T32-CA009207, K30-UL1TR00457, HHSN272201400008C, 7R01AI081848-04, 1R01CA240924-01]
  4. Damon Runyon Cancer Research Foundation [CI-98-18]
  5. Stand Up To Cancer, a program of the Entertainment Industry Foundation
  6. Society for Immunotherapy of Cancer
  7. Lustgarten Foundation
  8. Mark Foundation for Cancer Research

Ask authors/readers for more resources

Background: Patients with lung cancers may have disproportionately severe coronavirus disease 2019 (COVID-19) outcomes. Understanding the patient-specific and cancer-specific features that impact the severity of COVID-19 may inform optimal cancer care during this pandemic. Patients and methods: We examined consecutive patients with lung cancer and confirmed diagnosis of COVID-19 (n = 102) at a single center from 12 March 2020 to 6 May 2020. Thresholds of severity were defined a priori as hospitalization, intensive care unit/intubation/do not intubate ([ICU/intubation/DNI] a composite metric of severe disease), or death. Recovery was defined as >14 days from COVID-19 test and >3 days since symptom resolution. Human leukocyte antigen (HLA) alleles were inferred from MSK-IMPACT (n = 46) and compared with controls with lung cancer and no known non-COVID-19 (n = 5166). Results: COVID-19 was severe in patients with lung cancer (62% hospitalized, 25% died). Although severe, COVID-19 accounted for a minority of overall lung cancer deaths during the pandemic (11% overall). Determinants of COVID-19 severity were largely patient-specific features, including smoking status and chronic obstructive pulmonary disease [odds ratio for severe COVID-19 2.9, 95% confidence interval 1.07-9.44 comparing the median (23.5 pack-years) to never-smoker and 3.87, 95% confidence interval 1.35-9.68, respectively]. Cancer-specific features, including prior thoracic surgery/radiation and recent systemic therapies did not impact severity. Human leukocyte antigen supertypes were generally similar in mild or severe cases of COVID-19 compared with non-COVID-19 controls. Most patients recovered from COVID-19, including 25% patients initially requiring intubation. Among hospitalized patients, hydroxychloroquine did not improve COVID-19 outcomes. Conclusion: COVID-19 is associated with high burden of severity in patients with lung cancer. Patient-specific features, rather than cancer-specific features or treatments, are the greatest determinants of severity.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available